Please login to the form below

Not currently logged in
Email:
Password:

SGLT2

This page shows the latest SGLT2 news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

The SGLT2 inhibitor could be the first new drug in 15 years that slows kidney damage development. ... Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted

Latest news

More from news
Approximately 9 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Figure 1 (pictured right) shows the position of the DPP4/SGLT2 market for the last four months to March 2017 in English GP practices compared to the previous Tertial (four months). ... In contrast Jardiance and Vipidia are still growing where Jardiance

  • Deal Watch November 2015 Deal Watch November 2015

    Sotagliflozin is an oral dual inhibitor of sodium-glucose cotransporters type 1 and 2 (SGLT1 &SGLT2) which are responsible for glucose reabsorption by the GI tract and kidney respectively.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. “ ... The potential for the SGLT2 class of treatments which Forxiga is the first to launch, is tremendous.”.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics